Gerhard Hildebrandt

@drghildebrandt

Tweets and opinions are my own and are not endorsements or medical advice.

United States
Vrijeme pridruživanja: prosinac 2016.

Tweetovi

Blokirali ste korisnika/cu @drghildebrandt

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @drghildebrandt

  1. proslijedio/la je Tweet

    BJH Top cited paper: R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis

    Poništi
  2. 3. velj

    Worth a detailed look: High-Dose Chemotherapy With HSCT for High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes .

    Poništi
  3. 3. velj

    Cost coverage solutions are urgently needed - FDA approvals without a financial strategy plan in place can result in substantial financial burden and harm to both patients and institutions.

    Poništi
  4. proslijedio/la je Tweet

    Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients | Bone Marrow Transplantation

    Poništi
  5. proslijedio/la je Tweet
    1. velj

    Anti infective prophylaxis EBMT recommendations after CAR-T Cell infusion, now in

    Poništi
  6. 3. velj

    Just some food for thought for those who enjoy Super Bowl food.....

    Poništi
  7. 1. velj
    Poništi
  8. 1. velj

    Final talk of the day given by our fellow Dr Qasrawi on Benign Hematology. Incredible reminder of what is going on in that field !

    Poništi
  9. 1. velj

    Our nurse practitioners Jill Sewell and Amy Meijer presenting on probably the most important but sometimes neglected aspects of cancer care: survivorship and supportive care ⁦⁩ ⁦⁩ at our 4th Review in Hematology

    Poništi
  10. 1. velj

    Fellows on stage presenting at the division of Hematology‘s 4th Annual Review.

    Poništi
  11. 1. velj

    Welcome Dr Chait Igaravarapu to the Division of Hematology , who has been trained in BMT and in CAR-T therapy by my long standing friend and colleague David Miklos at Stanford and with interest in cellular therapy. Just joined us in December 2019

    Poništi
  12. 1. velj

    Engaging the next generation of hematologists - Dr Chacko, fellow in our program, presenting on Hodgkin Disease

    Poništi
  13. 1. velj

    Our newest team member Dr Igaravarapu presenting on NHL and squeezing an „Elefant“ in a „small box“ - great job bringing NHL down to the most recent the essentials !

    Poništi
  14. 1. velj

    Great turnout - every year a continuous growth in attendance ! My thank you to everyone coming today and spending their Saturday here with us ! ⁦⁩ ⁦⁩ Save the date for next year Feb 6 2021 for the 5th Annual Hematology Review!

    Poništi
  15. 1. velj

    Dr Krem kicking off the afternoon session - CNS lymphoma treatment ⁦⁩ ⁦

    Poništi
  16. 1. velj

    With improving long term survival, secondary malignancies gain and need to gain more attention. Dr Munker presenting at our 4th Review on Hematology ⁦⁩ ⁦

    Poništi
  17. 1. velj

    Dr Roger Herzig on MDS - always great listening to one of the best ⁦⁩ ⁦

    Poništi
  18. 1. velj

    „Maintenance therapy in AML - are we there yet?“ Dr Ramlal is giving us an exciting update on what to do after consolidation after AML ⁦⁩ ⁦

    Poništi
  19. 1. velj

    All we need to know about CML drug therapy - great learning from our Hem BMT pharmacist Jessica Cupac ⁦⁩ ⁦

    Poništi
  20. 1. velj
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·